Ontario Renal Reporting System (ORRS)
Chronic Renal Failure Patients on
Renal Replacement Therapy

FOLLOW-UP (HEMODIALYSIS)-2011

Fax/Upload THIS CONFIDENTIAL INFORMATION TO: Ontario Renal Network c/o Cancer Care Ontario 620 University Avenue, 15th Floor Toronto, Ontario M5G 2L7 Phone: 416-971-9800 x 2924 Fax: 416-217-1822



Please complete one follow-up form for every living hemodialysis patient being treated at your centre on October 31, 2011.	
(Patient label may be attached if same information is provided.)	
Hospital City:	

Hospital Name:		Hospita	al Number:		
Patient Last Name:			Affix patient label, if available.		
Patient First and Middle Names:					
Current Health Card Number:					
Province of Health Card:					
Current Postal Code:					
Date of Birth: / /					
1. Provide complete details on the latest available	-		. Date cannot exceed December 31, 2011. Laboratory Date of Test		Test
Test	Re	ference Range*	Results	(MON/YYYY)	Not Done
Hemoglobin (g/L) (pre-dialysis)	60-140 g/L		g/L	/	
Creatinine (µmol/L) (pre-dialysis)	300-1,500 μmol/L			/L /	
Urea (mmol/L) (pre-dialysis)	15-40 mmol/L		mmol	l/L /	
Urea (mmol/L) (post-dialysis)	5-20 mmol/L		mmol	I/L Should be the same date as above.	
□ Serum bicarbonate (mmol/L) (pre-dialysis) <u>OR</u> □ Serum CO ₂ (mmol/L) (pre-dialysis)	20-30 mmol/L		mmol	l/L _ _ / _ _ _ _	
Serum calcium (mmol/L) (pre-dialysis)	Various ranges-please specify:		mmol	l/L /	
	□ 2.22-2.62	mmol/L uncorrected mmol/L corrected mmol/L ionized			
Serum phosphate (mmol/L) (pre-dialysis)	1.5-1.8 mmol/L		mmol/	/L /	
Serum albumin (g/L) Serum parathormone (PTH) (pmol/L; ng/L or pg/ml)	25-50 g/L Various ranges—please specify: □ 1.3-7.6 pmol/L □ 18-73 ng/L □ 10-65 pg/ml		g/L 	/ /	
Ferritin (within nearest six months) (pmol/L or μ g/L)	50-500 pmol			/	
	Males 14-610 µg/L Females 8-125 µg/L		□ pmol/L □ µg/I	L	
Iron profile (for example, % saturation, serum iron,	🗆 Iron satura	ation (25%-50%)		/	
transferrin, TIBC)	 Serum iron (9-32 µmol/L) and TIBC (45-81 µmol/L) Serum iron (9-32 µmol/L) and Transferrin (2.0-4.0g/L) 				
					_
Diabetic? \Box No \Box Yes \rightarrow If yes: HbA _{1c}	4%-12% (0.04	ŀ-0.12)	%	/	
 Is the patient currently receiving erythropoietin? check "Yes.") 	(If patient is t	emporarily on hold from	n erythropoietin on O	ctober 31 but typically receives it,	
\Box No \Box Yes \rightarrow If yes: Product used:	Eprex	Aranesp	Other		
Route of administration:	□ IV	□ Subcutaneously			
Frequency of administration:	□ Weekly	Every two weeks	\Box Every three wee	eks \Box Monthly \Box Other:	
Total dose within period of a	administratior	n:	-		

* Will depend on laboratory procedures.



